Expanded Access for Anti-IL8
Primary Purpose
Status
No longer available
Phase
Locations
Study Type
Expanded Access
Intervention
Anti-IL8
Sponsored by

About this trial
This is an expanded access trial
Eligibility Criteria
Sites / Locations
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05210894
Brief Title
Expanded Access for Anti-IL8
Study Type
Expanded Access
2. Study Status
Record Verification Date
May 2022
Overall Recruitment Status
No longer available
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Bristol-Myers Squibb
4. Oversight
5. Study Description
Brief Summary
This is an expanded access designed to provide access to Anti-IL8 for eligible participants.
6. Conditions and Keywords
7. Study Design
8. Arms, Groups, and Interventions
Intervention Type
Biological
Intervention Name(s)
Anti-IL8
10. Eligibility
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bristol-Myers Squibb
Organizational Affiliation
Bristol-Myers Squibb
Official's Role
Study Director
12. IPD Sharing Statement
Links:
URL
https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Description
BMS Clinical Trial Information
URL
https://www.bmsstudyconnect.com/s/US/English/USenHome
Description
BMS Clinical Trial Patient Recruiting
URL
https://www.bms.com/healthcare-providers/early-patient-access-to-investigational-medicine/investigational-drugs-available.html
Description
Pre-Approval Access (PAA) Healthcare Practitioner Requests
URL
https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm
Description
FDA Safety Alerts and Recalls
Learn more about this trial
Expanded Access for Anti-IL8
We'll reach out to this number within 24 hrs